866-997-4948(US-Canada Toll Free)

Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Cancer

No. of Pages : 58 Pages


Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline Review, H2 2012

Global Markets Directs, 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). Adrenocortical Carcinoma (Adrenal Cortex Cancer) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Adrenocortical Carcinoma (Adrenal Cortex Cancer).
  • A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Content

Table of Content 2
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) 8
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics under Development by Companies 10
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Products under Development by Companies 17
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Products under Investigation by Universities/Institutes 18
Companies Involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Development 19
Pfizer Inc. 19
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Inlyta - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Seneca Valley Virus-001 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
mitotane - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Etoposide + Doxorubicin + Cisplatin + Mitotane - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 32
Streptozocin + Mitotane - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
G-CSF + Pegfilgrastim + Cisplatin + Doxorubicin + Etoposide + Mitotane - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 36
Doxorubicin + Vincristine + Etoposide + Mitotane - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 38
Mitotane + Cixutumumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Etoposide + Doxorubicin + Cisplatin + Mitotane - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Streptozotocin + Mitotane - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Mitotane + Doxorubicin + Vincristine + Etoposide + XR9576 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 44
Cisplatin + Taxotere - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AT-101 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
cixutumumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Gemcitabine + Capecitabine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Gemcitabine + Metronomic 5-Fluorouracil - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
decitabine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
mitotane - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Drug Profile Updates 52
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Discontinued Products 55
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics - Dormant Products 56

Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Table


Number of Products Under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2012 8
Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Pfizer Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Drug Profile Updates 52
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Discontinued Products 55
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Dormant Products 56

List of Chart


Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2012 8
Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *